Back to Search
Start Over
The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients
- Source :
- Europe PubMed Central
-
Abstract
- Despite the relative lack of data, nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-sparing regimens are increasingly prescribed in clinical practice in treatment-experienced HIV-1 infected patients. We aimed to assess the frequency of NRTI-sparing regimens among these subjects, and to evaluate and compare their safety and tolerability. Patients were included if enrolled in the currently ongoing cohorts (raltegravir and darunavir) of the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) Project. The duration of treatment with antiretroviral therapy was evaluated using the Kaplan-Meier curve and NRTI-sparing and NRTI-based regimens were compared using the log-rank test. From 2006 to 2011, 689 experienced patients were analyzed, of whom 210 (30.5%) were on NRTI-sparing regimens. Patients on NRTI-sparing regimens were older (p=0.004) and had higher median CD4+ cell counts (p=0.002) than patients on NRTI-based regimens. The most frequent combination regimens were raltegravir plus darunavir/ritonavir (n=65; 30.95%) among patients on NRTI-sparing regimen and tenofovir DF/emtricitabine plus darunavir/ritonavir in the NRTI-containing group (n=102; 21.3%). There was no difference between groups in terms of total withdrawal, treatment discontinuation was more likely due to therapeutic failure in NRTI-sparing regimen. NRTI-sparing regimens should be evaluated in a prospective randomized trial. © 2013 Bentham Science Publishers.
- Subjects :
- Adult
Male
medicine.medical_specialty
HIV Infections
Pharmacology
Emtricitabine
Durability
immune system diseases
Antiretroviral Therapy, Highly Active
Virology
Internal medicine
NRTI-sparing regimen
Humans
Medicine
HIV Infection
Nucleoside
Prospective Studies
Treatment Failure
Darunavir
Aged
integumentary system
Reverse-transcriptase inhibitor
business.industry
virus diseases
Nucleosides
Middle Aged
biochemical phenomena, metabolism, and nutrition
Raltegravir
Antiretroviral therapy
Reverse Transcriptase Inhibitor
Discontinuation
Prospective Studie
Regimen
Infectious Diseases
Withholding Treatment
Tolerability
HIV-1
Reverse Transcriptase Inhibitors
Female
Ritonavir
Safety
business
Human
medicine.drug
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Europe PubMed Central
- Accession number :
- edsair.doi.dedup.....5adc1253b6fa2bac0e3cc3a8c125f063